A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Tazemetostat (Primary)
- Indications Rhabdoid tumour; Synovial sarcoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Epizyme
- 02 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 02 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
- 01 Sep 2016 Planned number of patients changed from 84 to 108.